Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction

Detalles Bibliográficos
Autores principales: Fu, Wenyu, Chen, Yujianan, Wang, Kaidi, Hettinghouse, Aubryanna, Hu, Wenhuo, Wang, Jing-Quan, Lei, Zi-Ning, Chen, Zhe-Sheng, Stapleford, Kenneth A., Liu, Chuan-ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Higher Education Press 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673315/
https://www.ncbi.nlm.nih.gov/pubmed/33210243
http://dx.doi.org/10.1007/s13238-020-00803-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673315/
https://www.ncbi.nlm.nih.gov/pubmed/33210243
http://dx.doi.org/10.1007/s13238-020-00803-w

Ejemplares similares